Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12

AUTHORS

Per Svenningsson, Anders Johansson, Dag Nyholm, Panagiota Tsitsi, Fredrik Hansson, Clas Sonesson, Joakim Tedroff

ABSTRACT

IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson's disease (PD). The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controlled trial. PD patients with peak-dose dyskinesia were randomized to placebo or IRL790 treatment (1:3 ratio) for 4 weeks. Study drug was given as an adjunct treatment to the patients' regular stable antiparkinsonian medication. Dosing was individually titrated for 14 days, whereafter dosing was kept stable for an additional 14 days. Fifteen patients were randomized to treatment and 13 patients completed the 4-week treatment. Adverse events were mostly reported during the titration phase of the trial. They were mainly central nervous system related and could be mitigated by dose adjustments. There were no serious adverse events. There were no clinically significant changes in vital signs, electrocardiogram, and laboratory parameters due to the treatment. The average dose in the stable dose phase was 18 mg daily, yielding a 2-h post-dose plasma concentration of average 229 nM on day 28. Assessments for motor function showed a numeric reduction in dyskinesia. It is concluded that IRL790 can be safely administered to patients with advanced PD. The results will be of guidance for the design of phase 2 studies. More... »

PAGES

35

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41531-018-0071-3

DOI

http://dx.doi.org/10.1038/s41531-018-0071-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1110321380

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30534585


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Karolinska University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Department of Clinical Neuroscience, Karolinska Institutet, 171 77, Stockholm, Sweden", 
            "Department of Neurology, Karolinska University Hospital, 171 76, Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Svenningsson", 
        "givenName": "Per", 
        "id": "sg:person.01126744436.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126744436.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Karolinska University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.24381.3c", 
          "name": [
            "Department of Clinical Neuroscience, Karolinska Institutet, 171 77, Stockholm, Sweden", 
            "Department of Neurology, Karolinska University Hospital, 171 76, Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johansson", 
        "givenName": "Anders", 
        "id": "sg:person.011403770272.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011403770272.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Uppsala University", 
          "id": "https://www.grid.ac/institutes/grid.8993.b", 
          "name": [
            "Department of Neuroscience, Neurology, Uppsala University, 751 85, Uppsala, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nyholm", 
        "givenName": "Dag", 
        "id": "sg:person.01342231771.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342231771.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Karolinska Institute", 
          "id": "https://www.grid.ac/institutes/grid.4714.6", 
          "name": [
            "Department of Clinical Neuroscience, Karolinska Institutet, 171 77, Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsitsi", 
        "givenName": "Panagiota", 
        "id": "sg:person.013770602303.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013770602303.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Clinical Trial Consultants, Dag Hammarskj\u00f6ldsv\u00e4g 13, 752 37, Uppsala, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hansson", 
        "givenName": "Fredrik", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Integrative Research Laboratories AB, Arvid Wallgrens backe 20, 413 46, G\u00f6teborg, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sonesson", 
        "givenName": "Clas", 
        "id": "sg:person.0655614315.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655614315.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Karolinska Institute", 
          "id": "https://www.grid.ac/institutes/grid.4714.6", 
          "name": [
            "Department of Clinical Neuroscience, Karolinska Institutet, 171 77, Stockholm, Sweden", 
            "Integrative Research Laboratories AB, Arvid Wallgrens backe 20, 413 46, G\u00f6teborg, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tedroff", 
        "givenName": "Joakim", 
        "id": "sg:person.0751653525.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751653525.88"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.parkreldis.2016.06.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009567233"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.94.7.3363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011757648"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.neuroscience.2013.05.048", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023162741"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/cercor/bhv231", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027355201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35075076", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031257159", 
          "https://doi.org/10.1038/35075076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35075076", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031257159", 
          "https://doi.org/10.1038/35075076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031991474", 
          "https://doi.org/10.1038/nm875"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031991474", 
          "https://doi.org/10.1038/nm875"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbr.2014.01.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036032617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)60683-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036458868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/syn.21805", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036609682"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.parkreldis.2004.11.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050183243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.parkreldis.2004.11.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050183243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000002285", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064353306"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000002285", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064353306"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0000000000002285", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064353306"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.41.2_part_1.202", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064369793"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/187152711797247885", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069221673"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3233/jpd-2012-11071", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078770582"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/mds.27261", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099615253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.parkreldis.2018.01.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100319249"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson's disease (PD). The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controlled trial. PD patients with peak-dose dyskinesia were randomized to placebo or IRL790 treatment (1:3 ratio) for 4 weeks. Study drug was given as an adjunct treatment to the patients' regular stable antiparkinsonian medication. Dosing was individually titrated for 14 days, whereafter dosing was kept stable for an additional 14 days. Fifteen patients were randomized to treatment and 13 patients completed the 4-week treatment. Adverse events were mostly reported during the titration phase of the trial. They were mainly central nervous system related and could be mitigated by dose adjustments. There were no serious adverse events. There were no clinically significant changes in vital signs, electrocardiogram, and laboratory parameters due to the treatment. The average dose in the stable dose phase was 18\u2009mg daily, yielding a 2-h post-dose plasma concentration of average 229\u2009nM on day 28. Assessments for motor function showed a numeric reduction in dyskinesia. It is concluded that IRL790 can be safely administered to patients with advanced PD. The results will be of guidance for the design of phase 2 studies.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/s41531-018-0071-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1053024", 
        "issn": [
          "2373-8057"
        ], 
        "name": "npj Parkinson's Disease", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "Safety and tolerability of IRL790 in Parkinson\u2019s disease with levodopa-induced dyskinesia\u2014a phase 1b trial", 
    "pagination": "35", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c04d0286c6ec6367e9f99dc38b681563b503f569edc64da41b56173a3af48405"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30534585"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101675390"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41531-018-0071-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1110321380"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41531-018-0071-3", 
      "https://app.dimensions.ai/details/publication/pub.1110321380"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T08:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000309_0000000309/records_106271_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/s41531-018-0071-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41531-018-0071-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41531-018-0071-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41531-018-0071-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41531-018-0071-3'


 

This table displays all metadata directly associated to this object as RDF triples.

171 TRIPLES      21 PREDICATES      45 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41531-018-0071-3 schema:about anzsrc-for:11
2 anzsrc-for:1109
3 schema:author Nb5e8a60acf12442eb6409d5b67a6aa8b
4 schema:citation sg:pub.10.1038/35075076
5 sg:pub.10.1038/nm875
6 https://doi.org/10.1002/mds.27261
7 https://doi.org/10.1002/syn.21805
8 https://doi.org/10.1016/j.bbr.2014.01.011
9 https://doi.org/10.1016/j.neuroscience.2013.05.048
10 https://doi.org/10.1016/j.parkreldis.2004.11.005
11 https://doi.org/10.1016/j.parkreldis.2016.06.005
12 https://doi.org/10.1016/j.parkreldis.2018.01.010
13 https://doi.org/10.1016/s0140-6736(14)60683-8
14 https://doi.org/10.1073/pnas.94.7.3363
15 https://doi.org/10.1093/cercor/bhv231
16 https://doi.org/10.1212/wnl.0000000000002285
17 https://doi.org/10.1212/wnl.41.2_part_1.202
18 https://doi.org/10.2174/187152711797247885
19 https://doi.org/10.3233/jpd-2012-11071
20 schema:datePublished 2018-12
21 schema:datePublishedReg 2018-12-01
22 schema:description IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson's disease (PD). The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controlled trial. PD patients with peak-dose dyskinesia were randomized to placebo or IRL790 treatment (1:3 ratio) for 4 weeks. Study drug was given as an adjunct treatment to the patients' regular stable antiparkinsonian medication. Dosing was individually titrated for 14 days, whereafter dosing was kept stable for an additional 14 days. Fifteen patients were randomized to treatment and 13 patients completed the 4-week treatment. Adverse events were mostly reported during the titration phase of the trial. They were mainly central nervous system related and could be mitigated by dose adjustments. There were no serious adverse events. There were no clinically significant changes in vital signs, electrocardiogram, and laboratory parameters due to the treatment. The average dose in the stable dose phase was 18 mg daily, yielding a 2-h post-dose plasma concentration of average 229 nM on day 28. Assessments for motor function showed a numeric reduction in dyskinesia. It is concluded that IRL790 can be safely administered to patients with advanced PD. The results will be of guidance for the design of phase 2 studies.
23 schema:genre research_article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf N1cf165981e9544abb281f5ba4d6a9b7f
27 N35ac227e6fc244c382073c81c0e18215
28 sg:journal.1053024
29 schema:name Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
30 schema:pagination 35
31 schema:productId N28b44d79257541e5ac90678950ef0b53
32 N37c778613af24c73b68a9222bc7e6688
33 Nc94972ef4d7643459f3dfe6afdb064d6
34 Nc9a9939c9bb549b5999052bc6ccaa362
35 Nd33d828ae98d4bec864801cf0c53543d
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110321380
37 https://doi.org/10.1038/s41531-018-0071-3
38 schema:sdDatePublished 2019-04-11T08:30
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher Nb9696950214b49edb3bc74be6cfdd798
41 schema:url https://www.nature.com/articles/s41531-018-0071-3
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N030fb3da746041089768fc8d6dd19606 rdf:first sg:person.013770602303.21
46 rdf:rest N7a6884e4e6db4b25943b353408d62da6
47 N1cf165981e9544abb281f5ba4d6a9b7f schema:issueNumber 1
48 rdf:type schema:PublicationIssue
49 N28b44d79257541e5ac90678950ef0b53 schema:name nlm_unique_id
50 schema:value 101675390
51 rdf:type schema:PropertyValue
52 N35ac227e6fc244c382073c81c0e18215 schema:volumeNumber 4
53 rdf:type schema:PublicationVolume
54 N37c778613af24c73b68a9222bc7e6688 schema:name pubmed_id
55 schema:value 30534585
56 rdf:type schema:PropertyValue
57 N6f9209b5222e4519b5f13f8b8552dea7 schema:name Clinical Trial Consultants, Dag Hammarskjöldsväg 13, 752 37, Uppsala, Sweden
58 rdf:type schema:Organization
59 N7a6884e4e6db4b25943b353408d62da6 rdf:first Na8df3ba431de4d94b6757c63e6b2c61d
60 rdf:rest Nabc122077dd54eba8b75c7b5c8b895c5
61 Na8df3ba431de4d94b6757c63e6b2c61d schema:affiliation N6f9209b5222e4519b5f13f8b8552dea7
62 schema:familyName Hansson
63 schema:givenName Fredrik
64 rdf:type schema:Person
65 Na93837a26e444a8892894a61d57d726e schema:name Integrative Research Laboratories AB, Arvid Wallgrens backe 20, 413 46, Göteborg, Sweden
66 rdf:type schema:Organization
67 Nabc122077dd54eba8b75c7b5c8b895c5 rdf:first sg:person.0655614315.85
68 rdf:rest Nc6f017c41604401bb1343ef42aab0f67
69 Nb0c51fd6b4864bc68f9d148278629a3d rdf:first sg:person.01342231771.02
70 rdf:rest N030fb3da746041089768fc8d6dd19606
71 Nb5e8a60acf12442eb6409d5b67a6aa8b rdf:first sg:person.01126744436.74
72 rdf:rest Ne1f1d2d9ed4342cf96e6aa1ba603fd3c
73 Nb9696950214b49edb3bc74be6cfdd798 schema:name Springer Nature - SN SciGraph project
74 rdf:type schema:Organization
75 Nc6f017c41604401bb1343ef42aab0f67 rdf:first sg:person.0751653525.88
76 rdf:rest rdf:nil
77 Nc94972ef4d7643459f3dfe6afdb064d6 schema:name doi
78 schema:value 10.1038/s41531-018-0071-3
79 rdf:type schema:PropertyValue
80 Nc9a9939c9bb549b5999052bc6ccaa362 schema:name readcube_id
81 schema:value c04d0286c6ec6367e9f99dc38b681563b503f569edc64da41b56173a3af48405
82 rdf:type schema:PropertyValue
83 Nd33d828ae98d4bec864801cf0c53543d schema:name dimensions_id
84 schema:value pub.1110321380
85 rdf:type schema:PropertyValue
86 Ne1f1d2d9ed4342cf96e6aa1ba603fd3c rdf:first sg:person.011403770272.99
87 rdf:rest Nb0c51fd6b4864bc68f9d148278629a3d
88 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
89 schema:name Medical and Health Sciences
90 rdf:type schema:DefinedTerm
91 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
92 schema:name Neurosciences
93 rdf:type schema:DefinedTerm
94 sg:journal.1053024 schema:issn 2373-8057
95 schema:name npj Parkinson's Disease
96 rdf:type schema:Periodical
97 sg:person.01126744436.74 schema:affiliation https://www.grid.ac/institutes/grid.24381.3c
98 schema:familyName Svenningsson
99 schema:givenName Per
100 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126744436.74
101 rdf:type schema:Person
102 sg:person.011403770272.99 schema:affiliation https://www.grid.ac/institutes/grid.24381.3c
103 schema:familyName Johansson
104 schema:givenName Anders
105 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011403770272.99
106 rdf:type schema:Person
107 sg:person.01342231771.02 schema:affiliation https://www.grid.ac/institutes/grid.8993.b
108 schema:familyName Nyholm
109 schema:givenName Dag
110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342231771.02
111 rdf:type schema:Person
112 sg:person.013770602303.21 schema:affiliation https://www.grid.ac/institutes/grid.4714.6
113 schema:familyName Tsitsi
114 schema:givenName Panagiota
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013770602303.21
116 rdf:type schema:Person
117 sg:person.0655614315.85 schema:affiliation Na93837a26e444a8892894a61d57d726e
118 schema:familyName Sonesson
119 schema:givenName Clas
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655614315.85
121 rdf:type schema:Person
122 sg:person.0751653525.88 schema:affiliation https://www.grid.ac/institutes/grid.4714.6
123 schema:familyName Tedroff
124 schema:givenName Joakim
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751653525.88
126 rdf:type schema:Person
127 sg:pub.10.1038/35075076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031257159
128 https://doi.org/10.1038/35075076
129 rdf:type schema:CreativeWork
130 sg:pub.10.1038/nm875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031991474
131 https://doi.org/10.1038/nm875
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1002/mds.27261 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099615253
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1002/syn.21805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036609682
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1016/j.bbr.2014.01.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036032617
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1016/j.neuroscience.2013.05.048 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023162741
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1016/j.parkreldis.2004.11.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050183243
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1016/j.parkreldis.2016.06.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009567233
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1016/j.parkreldis.2018.01.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100319249
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1016/s0140-6736(14)60683-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036458868
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1073/pnas.94.7.3363 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011757648
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1093/cercor/bhv231 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027355201
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1212/wnl.0000000000002285 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064353306
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1212/wnl.41.2_part_1.202 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064369793
156 rdf:type schema:CreativeWork
157 https://doi.org/10.2174/187152711797247885 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069221673
158 rdf:type schema:CreativeWork
159 https://doi.org/10.3233/jpd-2012-11071 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078770582
160 rdf:type schema:CreativeWork
161 https://www.grid.ac/institutes/grid.24381.3c schema:alternateName Karolinska University Hospital
162 schema:name Department of Clinical Neuroscience, Karolinska Institutet, 171 77, Stockholm, Sweden
163 Department of Neurology, Karolinska University Hospital, 171 76, Stockholm, Sweden
164 rdf:type schema:Organization
165 https://www.grid.ac/institutes/grid.4714.6 schema:alternateName Karolinska Institute
166 schema:name Department of Clinical Neuroscience, Karolinska Institutet, 171 77, Stockholm, Sweden
167 Integrative Research Laboratories AB, Arvid Wallgrens backe 20, 413 46, Göteborg, Sweden
168 rdf:type schema:Organization
169 https://www.grid.ac/institutes/grid.8993.b schema:alternateName Uppsala University
170 schema:name Department of Neuroscience, Neurology, Uppsala University, 751 85, Uppsala, Sweden
171 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...